Illumina Buys Helixis for Up to $105M; Unveils Sub-$15K Benchtop PCR Platform

Illumina has acquired real-time PCR and nucleic acid-analysis firm Helixis for up to $105 million, and has launched a new benchtop PCR instrument developed by Helixis that it said will cost about a quarter the price of existing systems while delivering the same level of performance.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.